Yissum - Research Development Company of the Hebrew University

Libraries of Drug Candidates from Peptides and Proteins

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Heterocyclic compounds having a relatively flexible backbone are used to create combinatorial libraries that permit screening for lead compounds and selection of drug candidates for a variety of uses in human and veterinary medicine as well as in agriculture. The compounds of the library generally differ in ring size and chirality of substituents on the ring. Also disclosed are methods for providing and screening these libraries, preferably in an automated or computerizable manner, such as by using a computer program to virtually screen the compounds in order to identify those that are predicted to have bioactive conformations that should give rise to desirable biological effects.
Keywords: libraries


Project ID : 6-2006-53

Description of the technology

Combinatorial libraries of heterocyclic compounds

Category

Drug Discovery, Small Molecules, Conversion of Peptides and Proteins into drug leads

Development Stage

Ongoing projects in various stages

Patent Status

Patents published in U.S. and Europe, filed in IsraelPCT publication number – WO 03/059876

Market Size

The global protein therapeutic market was valued in excess of US$ 57 billion in 2006, growing at a CAGR of 12.83% till 2010

Highlights

  • Preparing libraries of backbone cyclized peptidomietics and macromoecules with conformational diversity, based on active residues from proteins and/or active peptides for screening and selecting drug lead candidates, having improved activity, selectivity, metabolic stability and enhanced intestinal permeability. This technology is applicable to a variety of indications in human medicine, veterinary medicine and in agriculture

  • Applying this novel technology to a patented target molecule facilitates the speedy development of drug leads

Our Innovation

  • A new technology that converts active regions in proteins and peptides into orally available drug leads.

Key Features

  • Faster, more reliable, identification of drug leads

  • Enables faster pharmacological studies

Development Milestones

  • Cooperation with companies with defined clinical goals and patented molecules to develop drug leads

The Opportunity

  • Licensing agreements with cooperation partners to convert their peptides and proteins into drug leads using new technology

  • Libraries of drug candidates sold to partners

Project manager

Ariela Markel
VP, Business Development, Healthcare

Project researchers

Chaim Gilon
HUJI, Faculty of Science
The Institute of Chemistry

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • small molecule

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.